Alignment Healthcare, Inc. (NASDAQ:ALHC) President of Markets, Dawn Christine Maroney, recently sold 10,151 shares of company stock, totaling approximately $49,130. The transactions were executed on March 28, 2024, with share prices ranging from $4.73 to $4.935.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units. This was not a discretionary sale, indicating that the shares were sold as a mandatory action in line with the executive's compensation agreement rather than a strategic trading decision.
Following the sale, Maroney retains direct ownership of 1,976,097 shares in the company. The specific transactions were reported to have taken place at a weighted-average price of $4.84 per share. This information is significant for current and potential investors as it reflects the latest insider trading activity within Alignment Healthcare, providing insights into executive actions and their current stakes in the company.
Investors and stakeholders of Alignment Healthcare can request detailed information about the exact number of shares sold at each price point within the provided range, if needed. This transparency is part of the company's commitment to maintaining open communication channels with its shareholders.
The reported transactions were filed in accordance with the Securities and Exchange Commission's requirements, which necessitate timely disclosure of such activities by company insiders.
InvestingPro Insights
As Alignment Healthcare, Inc. (NASDAQ:ALHC) navigates through its financial landscape, certain metrics and analyst insights from InvestingPro can provide a deeper understanding of the company's current valuation and market performance. According to InvestingPro data, Alignment Healthcare holds a market capitalization of $937.33 million and is trading at a high Price / Book multiple of 5.97 as of the last twelve months ending Q4 2023. This suggests that the company's stock is trading at a premium relative to its book value, which could be of interest to value-oriented investors.
Despite significant revenue growth of 27.16% over the last twelve months as of Q4 2023, Alignment Healthcare has not been profitable during this period, with a reported operating income margin of -6.9%. The company's P/E ratio stands at -6.39, reflecting its lack of profitability in the recent past. This is corroborated by an InvestingPro Tip, which indicates that analysts do not expect the company to be profitable this year.
Another InvestingPro Tip highlights that the stock has experienced a notable decline over the last three months, with a price total return of -42.39%. This could attract investors looking for potential turnaround candidates or those willing to bet on a recovery. For those considering deeper analysis, there are additional InvestingPro Tips available at https://www.investing.com/pro/ALHC, which could further inform investment decisions. To access these insights, investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
It should be noted that the company's next earnings date is slated for May 2, 2024, which could bring pivotal information affecting the stock's trajectory. With a total of 9 InvestingPro Tips available, investors have ample data points to consider when assessing the potential risks and opportunities associated with Alignment Healthcare.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.